Trial Profile
A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Peptide vaccines (Primary) ; Peptide vaccines (Primary)
- Indications Malignant melanoma; Uveal melanoma
- Focus Adverse reactions; Pharmacodynamics
- Acronyms Mel64
- 26 Mar 2020 Status changed from active, no longer recruiting to completed.
- 27 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2018 Planned number of patients changed from 47 to 25.